Two Decades of Data Show Steady Gains in Survival After Stem Cell Transplants for Leukemia

Allogeneic hematopoietic cell transplantation remains the single most powerful weapon in the fight against higher-risk acute myeloid leukemia, a cancer of the blood and bone marrow that can progress with terrifying speed. Now, one of the most comprehensive national analyses ever assembled has traced how the outcomes of this demanding procedure have evolved across nearly two decades of clinical practice, offering both reassurance and a sober reality check for patients and physicians alike. The findings, drawn from more than a thousand adult transplants performed in Austria, reveal modest but meaningful improvements in survival, alongside enduring challenges from relapse and treatment-related toxicity that continue to define the limits of the therapy.

The study, published in Annals of Hematology by a team of Austrian transplant specialists led by Alexandra Donschachner and Johannes Clausen, analyzed a national cohort of 1,112 adult AML patients who received allogeneic stem cell transplants between 2000 and 2017. Nearly half of the patients were women, the median age at transplantation was 51 years, and 63 percent received grafts from unrelated donors. Crucially, the investigators compared outcomes across three consecutive six-year periods, 2000 to 2005, 2006 to 2011, and 2012 to 2017, using broadly comparable conditioning regimens, supportive care standards, and donor selection criteria throughout. That consistency is what makes the dataset scientifically valuable: when treatment frameworks remain stable, shifts in survival can be attributed with greater confidence to genuine changes in patient characteristics and clinical practice rather than to fluctuations in protocol.

The headline numbers tell a story of incremental progress rather than dramatic breakthrough. Five-year overall survival stood at 38 percent for patients transplanted in the earliest era, rose to 45 percent in the middle period, and then settled at 35 percent in the most recent cohort. Taken together, these figures illustrate a pattern that transplant physicians know well: gains in one domain are often offset by pressures in another. Across the entire cohort, the estimated cumulative incidence of non-relapse mortality, meaning death from causes other than the leukemia itself, was 27 percent, while the relapse rate reached 37 percent. In other words, for roughly one patient in four, the procedure itself or its complications proved fatal, and for more than one in three, the underlying malignancy returned.

One of the most revealing aspects of the analysis lies in how patient characteristics shifted over the two decades. Patients transplanted in later years were older on average, and a higher proportion underwent transplantation while in their first complete remission, the point at which chemotherapy has cleared detectable leukemic cells and the disease is at its most controllable. At the same time, the use of unrelated donors expanded steadily, as did reliance on peripheral blood stem cells rather than bone marrow as the graft source. Each of these trends reflects genuine advances: better HLA typing and donor registries made unrelated transplantation safer and more feasible, while improved remission induction allowed more patients to reach transplant in favorable disease status. Yet an aging and more heavily pretreated population brings its own vulnerabilities, including greater susceptibility to organ toxicity, infections, and graft-versus-host disease.

Perhaps the most clinically striking result concerns the subgroup of patients who arrived at transplantation with active, measurable disease, the hardest-to-treat scenario in AML. In this group, overall survival rose from 15 percent in the earliest era to 28 percent in the most recent, a trend that approached statistical significance despite the modest number of patients involved. Even more compelling, relapse incidence in these patients fluctuated significantly across the three periods, falling from 58 percent to 40 percent and then rising again to 54 percent. The authors report this pattern with a p-value of 0.016, indicating that the variation is unlikely to be explained by chance alone. Transplanting a patient with uncontrolled leukemia is a gamble: the graft-versus-leukemia effect, in which donor immune cells attack residual malignant cells, can be lifesaving, but the disease is also primed to regrow. The fluctuations in relapse rates likely mirror changes in patient selection, conditioning intensity, and the availability of salvage therapies.

Why does the most recent cohort not show uniformly better results than its predecessors? The answer appears to lie in the evolving risk profile of the transplant population. As transplantation became available to older patients and to those with more aggressive or refractory disease biology, the population entering the procedure grew inherently sicker. A 35 percent five-year survival in a cohort that includes more elderly patients and more advanced disease may represent better medicine than a 38 percent survival in a younger, fitter population a decade earlier. This phenomenon, sometimes called the risk-shift paradox, complicates naive comparisons of survival statistics across eras and underscores why formal statistical adjustment for patient characteristics is essential in transplant research.

The technical backbone of allogeneic transplantation deserves attention to fully appreciate these findings. The procedure involves destroying a patient’s diseased bone marrow with high-dose chemotherapy, sometimes combined with radiation, and then infusing hematopoietic stem cells from a donor whose human leukocyte antigens, the molecular fingerprints the immune system uses to distinguish self from foreign, closely match those of the recipient. The donor cells repopulate the marrow and, critically, mount an immunological campaign against any residual leukemia. But the same immune machinery can attack the patient’s own tissues, producing graft-versus-host disease, a potentially devastating complication affecting the skin, liver, and gastrointestinal tract. Balancing the graft-versus-leukemia effect against graft-versus-host disease remains the central immunological tightrope of the field, and every improvement in donor matching, prophylaxis, and supportive care nudges that balance forward.

The national scope of the Austrian dataset gives it particular weight. Rather than aggregating results from a handful of high-volume academic centers, which can inflate outcomes through referral bias, the study captured the real-world performance of an entire country’s transplant program, drawing on the Austrian Stem Cell Transplant Registry and involving centers in Vienna, Graz, Innsbruck, and Linz. Registry-based designs of this kind answer a question that single-center studies cannot: what does this procedure actually deliver across the full spectrum of patients and institutions where it is performed today? The open-access publication also means that the full methodological detail, statistical models, and supplementary analyses are freely available to clinicians and researchers worldwide, an increasingly important standard in hematologic research.

What emerges from the analysis is neither triumph nor failure but something more honest: a portrait of a maturing therapy whose benefits are real but unevenly distributed. For patients in first complete remission, particularly those with favorable risk genetics, transplantation offers a genuine chance of long-term cure. For those with active disease at the time of the procedure, survival has improved, but the majority still face formidable odds. The trajectory over the two decades suggests that progress in this field arrives through the accumulation of small refinements, better donor selection, more sophisticated conditioning, improved antimicrobial strategies, and refined supportive care, rather than through any single transformative intervention.

Looking ahead, the study’s authors and the wider transplant community face a clear agenda. Reducing relapse, the leading cause of treatment failure in this cohort, remains the paramount challenge, and it will likely require integrating novel therapeutics, from targeted agents against specific leukemic mutations to cellular immunotherapies, into the peri-transplant period. Meanwhile, lowering non-relapse mortality through gentler conditioning regimens, better graft-versus-host disease prophylaxis, and improved management of infections could lift survival for the growing population of older patients. The Austrian data provide the essential baseline against which these future innovations must be measured, and they affirm a fundamental truth of modern oncology: in the decades-long effort to make bone marrow transplantation a reliable cure for acute myeloid leukemia, steady, measured progress continues, patient by patient and year by year.

Subject of Research: Long-term survival outcomes of allogeneic stem cell transplantation in adults with acute myeloid leukemia

Article Title: Long-term survival after allogeneic stem cell transplantation in patients with acute myeloid leukemia

Article References: Donschachner, A., Pregartner, G., Lindner, B., Berghold, A., Greinix, H., Rabitsch, W., Bauhofer, A., Nachbaur, D., Mitterbauer, M., Huber-Kraßnitzer, B., Cserna, J., Hetzenauer, G., Sill, H., Neumeister, P., & Clausen, J. (2026). Long-term survival after allogeneic stem cell transplantation in patients with acute myeloid leukemia. Annals of Hematology. https://doi.org/10.1007/s00277-026-07275-8

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07275-8

Keywords: acute myeloid leukemia, allogeneic stem cell transplantation, hematopoietic cell transplantation, overall survival, non-relapse mortality, relapse incidence, graft-versus-host disease, unrelated donors, hematologic cancer, Austrian Stem Cell Transplant Registry, prognosis, first complete remission